Back to Search
ALLISON MILLER, MD
MD
Dermatology Physician
NPI: 1275155806IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Dermatology PhysicianPrimary
Dermatology
Code: 207N00000X
83778(WI)
CMS Specialties
PrimaryDERMATOLOGY
Education
UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE
Class of 2020
Research & Publications (20)
Polar body emission requires a RhoA contractile ring and Cdc42-mediated membrane protrusion.
PMID 18804436·Dev Cell·2008
7-preclinical
Control of the cytokinetic apparatus by flux of the Rho GTPases.
PMID 18481962·Biochem Soc Trans·2008
7-preclinical
Norman Cousins Lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface.
PMID 18793712·Brain Behav Immun·2009
7-preclinical
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
PMID 19255312·J Clin Oncol·2009
3-trial
Inflammation versus glucocorticoids as purveyors of pathology during stress: have we reached the tipping point?
PMID 18675617·Biol Psychiatry·2008
8-other
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
PMID 18827613·J Thorac Oncol·2008
3-trial
Impact of musculoskeletal disease on quality of life in long-standing acromegaly.
PMID 18426816·Eur J Endocrinol·2008
8-other
Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer.
PMID 18281672·J Clin Oncol·2008
6-review
Elucidating the consequences of chronic stress on immune regulation and behavior in rheumatoid arthritis.
PMID 17920242·Brain Behav Immun·2008
6-review
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
PMID 17634483·J Clin Oncol·2007
3-trial
Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.
PMID 17607121·J Thorac Oncol·2007
3-trial
Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
PMID 17049403·Lung Cancer·2006
3-trial
Phase II study of carboplatin, irinotecan, and thalidomide in patients with advanced non-small cell lung cancer.
PMID 17409967·J Thorac Oncol·2006
3-trial
Temporal lobe anatomy and psychiatric symptoms in velocardiofacial syndrome (22q11.2 deletion syndrome).
PMID 16670653·J Am Acad Child Adolesc Psychiatry·2006
8-other
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004).
PMID 15893009·Lung Cancer·2005
3-trial
Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763.
PMID 15623609·Clin Cancer Res·2004
8-other
Rosuvastatin treatment reverses impaired coronary artery vasodilation in fructose-fed, insulin-resistant rats.
PMID 15044186·Am J Physiol Regul Integr Comp Physiol·2004
7-preclinical
Arachidonic acid-induced vasodilation of rat small mesenteric arteries is lipoxygenase-dependent.
PMID 12490584·J Pharmacol Exp Ther·2003
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1 S PARK ST
MADISON, WI 53715 - Phone
- (608) 287-2450
Quick Facts
- NPI
- 1275155806
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 6
- Publications
- 20
Are you this provider?
Claim Your Profile